Longeveron Inc. Common Stock
LGVNLongeveron Inc. (LGVN) is a biotechnology company focused on developing regenerative medicine therapies, particularly using cellular and molecular approaches to address aging-related diseases and chronic conditions. The company emphasizes treatments derived from proprietary mesenchymal stem cell technology and other biologics to promote tissue repair and restore health.
Company News
Longeveron Inc. completed a public offering of 5,882,354 Class A common stock and short-term warrants, raising approximately $5 million, with potential additional proceeds of $12.5 million from warrant exercises. The company plans to use funds for clinical development of laromestrocel targeting various medical conditions.
Longeveron presented positive long-term survival data for its Lomecel-B treatment in patients with Hypoplastic Left Heart Syndrome (HLHS). The data showed 100% 5-year survival and transplant-free rates, outperforming historical data. The findings support the potential of Lomecel-B as an adjunct therapy to improve outcomes for HLHS patients.
Annovis Bio, a late-stage clinical drug platform company, announced that its Founder, President, and CEO, Maria L. Maccecchini, Ph.D., will participate in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, including a company presentation and a panel discussion on non-amyloid approaches in Alzheimer's disease.
Longeveron announced positive results from its Phase 2a CLEAR MIND clinical trial of Lomecel-B in mild Alzheimer's disease, showing improvements in cognitive function, quality of life, and brain volume.
Longeveron Inc. announced that the U.S. FDA has granted Fast Track designation to its investigational cellular therapy Lomecel-B™ for the treatment of mild Alzheimer's Disease. This designation will expedite the clinical development and regulatory review of Lomecel-B™ for this indication.
